Neoadjuvant nivolumab

Phase 2Monoclonal antibody

TThe Netherlands Cancer Institute

Neoadjuvant nivolumab is one of 4 small molecule programs targeting Renal Cell Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal Cell CancerActive, not recruiting

Renal Cell CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Renal Cell Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

2 2

Yervoy

Bristol-Myers Squibb

Phase 1

2 3

Valemetostat

Bristol-Myers Squibb

Phase 1

1 4

Neoadjuvant nivolumab

TThe Netherlands Cancer Institute

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Active, not recruiting

Melanoma

NCT04949113

Q2 2029

Phase 2Active, not recruiting

Renal Cell Cancer

NCT05148546

Clinical

Trials by Indication[1]

Renal Cell Cancer1 trial

Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer

Active, not recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT05148546·69 enrolled

Melanoma1 trial

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

Active, not recruiting·TThe Netherlands Cancer Institute·Phase 3·NCT04949113·423 enrolled

Adjuvant Therapy1 trial

Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

Unknown status·UUniversitätsklinikum Hamburg-Eppendorf·Phase 3·NCT03700905·276 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Neoadjuvant nivolumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neoadjuvant nivolumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neoadjuvant nivolumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Netherlands Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: TThe Netherlands Cancer Institute

Neoadjuvant nivolumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2029

Trials by Indication[1]

Renal Cell Cancer1 trial

Melanoma1 trial

Adjuvant Therapy1 trial

References

Drug Info

Quick Facts

Related News